Membership Directory

Akebia Therapeutics, Inc.

Category: Drug Development
Phone: (617) 871-2098
Fax: (617) 871-2099
Location: Cambridge, MA

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia‐inducible factor biology and the commercialization of these products for patients with kidney disease. Akebia’s lead product candidate, AKB‐6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB‐6548 is being developed as a once-daily oral therapy which works through the inhibition of hypoxia‐inducible factor prolyl hydroxylase, leading to stabilization and increased levels of HIFα and therefore improved production of hemoglobin and red blood cells.

Back to list